Stockscreener 앱 받기
36.88
0.33%
0.12
전일 마감가:
$36.76
열려 있는:
$37.59
하루 거래량:
6.85M
Relative Volume:
1.52
시가총액:
$75.24B
수익:
$39.71B
순이익/손실:
$3.17B
주가수익비율:
10.71
EPS:
3.4423
순현금흐름:
$6.05B
1주 성능:
-1.71%
1개월 성능:
-8.49%
6개월 성능:
-13.37%
1년 성능:
+6.65%
1일 변동 폭
$36.85
$37.60
1주일 범위
$36.07
$38.26
52주 변동 폭
$33.67
$45.92
글락소스미스클라인 ADR Stock (GSK) Company Profile
글락소스미스클라인 ADR Stock (GSK) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-07-08 | 다운그레이드 | UBS | Buy → Neutral |
| 2024-05-30 | 개시 | Goldman | Neutral |
| 2024-03-04 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2024-02-13 | 업그레이드 | Citigroup | Neutral → Buy |
| 2024-01-23 | 개시 | Morgan Stanley | Equal-Weight |
| 2024-01-16 | 재개 | UBS | Buy |
| 2024-01-03 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-07-14 | 개시 | HSBC Securities | Reduce |
| 2023-03-17 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2023-02-27 | 재개 | Goldman | Buy |
| 2023-01-03 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2022-12-05 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2022-11-11 | 다운그레이드 | UBS | Neutral → Sell |
| 2022-09-15 | 업그레이드 | Credit Suisse | Underperform → Neutral |
| 2022-09-08 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-08-05 | 재개 | Morgan Stanley | Equal-Weight |
| 2022-07-21 | 재개 | Citigroup | Neutral |
| 2022-02-11 | 다운그레이드 | DZ Bank | Buy → Hold |
| 2021-11-05 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2021-06-24 | 업그레이드 | Deutsche Bank | Sell → Hold |
| 2021-03-23 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2021-02-04 | 다운그레이드 | Deutsche Bank | Hold → Sell |
| 2021-01-20 | 다운그레이드 | Credit Suisse | Neutral → Underperform |
| 2021-01-15 | 개시 | Deutsche Bank | Hold |
| 2020-11-02 | 업그레이드 | Liberum | Hold → Buy |
| 2020-09-29 | 개시 | Berenberg | Buy |
| 2020-02-12 | 다운그레이드 | Shore Capital | Hold → Sell |
| 2020-01-16 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2019-12-02 | 개시 | SVB Leerink | Outperform |
| 2019-11-21 | 업그레이드 | UBS | Neutral → Buy |
| 2019-10-11 | 업그레이드 | Cantor Fitzgerald | Hold → Buy |
| 2019-09-03 | 재개 | Citigroup | Neutral |
| 2019-09-03 | 업그레이드 | Societe Generale | Sell → Buy |
| 2019-08-13 | 재개 | JP Morgan | Neutral |
| 2019-06-17 | 재개 | Morgan Stanley | Underweight |
| 2019-03-08 | 다운그레이드 | Shore Capital | Buy → Hold |
| 2019-02-22 | 다운그레이드 | UBS | Buy → Neutral |
| 2019-01-14 | 다운그레이드 | Exane BNP Paribas | Outperform → Neutral |
| 2018-12-11 | 재개 | Jefferies | Buy |
| 2018-10-09 | 개시 | Guggenheim | Neutral |
| 2018-08-30 | 다운그레이드 | Liberum | Buy → Hold |
| 2018-04-04 | 업그레이드 | Exane BNP Paribas | Neutral → Outperform |
| 2018-03-22 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2018-02-09 | 업그레이드 | Kepler | Reduce → Hold |
모두보기
글락소스미스클라인 ADR 주식(GSK)의 최신 뉴스
GSK Plc ADR (NYSE: GSK) Has Outstanding Potential - Stocks Register
Sabin Sends More Marburg Vaccines for Rwanda’s Outbreak - GlobeNewswire Inc.
What Do Analysts Think About ICICI Bank Ltd. ADR’s (NYSE:IBN) Future? - Stocks Register
Weekly Upgrades and Downgrades - InvestorPlace
GSK Plc ADR (GSK): An Important Analyst Insights - Stocks Register
5 Stocks to Buy if You’re Concerned About US Market Valuations - Morningstar
21 Best Healthcare Companies to Invest In - Morningstar
Current share price is - GSK
D-Wave Quantum Inc (QBTS) rating initates by B. Riley Securities - Knox Daily
GSK's Studies On Depemokimab For Nasal Polyps Meet Primary Goals - Barchart
Ophthalmic Disease Therapeutics Market Analysis by Age-related Macular Degeneration, Diabetic Macular Edema, & Other Retinal Disorders - GlobeNewswire Inc.
GSK Plc ADR [GSK] is 5.59% higher this YTD. Is it still time to buy? - The DBT News
What You Didn’t Know About General Motors Company (NYSE: GM) This Week - Stocks Register
GSK’s Market Quandary: Decoding the Ups and Downs of 2023 - The InvestChronicle
Before You Invest, Make Sure You Check This ADT Inc (NYSE: ADT) Analysis - Stocks Register
What Are You Thinking About Investing In Medical Properties Trust Inc (NYSE: MPW) Stock? - Stocks Register
Why GSK Stock Rocketed Nearly 6% Skyward on Wednesday - sharewise
Introducing Our Rant Against GSK Plc ADR - US Post News
Balance Sheet Insights: GSK Plc ADR (GSK)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - The Dwinnex
Pilgrim’s Pride Corp. (PPC) receives an Equal-weight rating from Stephens - Knox Daily
Berenberg upgrades Carnival plc ADR (CUK) stock to a Hold - Knox Daily
JP Morgan analysts downgrades an Underweight rating for Organon & Co. (OGN) - Knox Daily
GSK Plc ADR (GSK) gets rating Downgrade from UBS - Knox Daily
GSK Plc ADR (GSK) Stock: A Comprehensive 52-Week Review - The InvestChronicle
Precidian to List First ADRhedged Securities in the U.S. on Cboe - Traders Magazine
Precidian to List First ADRhedged Securities in the U.S. on Cboe, Providing Exposure to Individual International Companies with an Embedded Currency Hedge - PR Newswire
Tenet Healthcare Corp. [THC] stock for 1,879,734 USD was sold by Ramsey R. Scott - Knox Daily
Ratio Analysis: Unpacking GSK Plc ADR (GSK)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
GSK Plc ADR [GSK] Insider Activity: An Update for Investors - Knox Daily
GSK Plc ADR (GSK) Stock: Navigating a Year of Stock Volatility - The InvestChronicle
Cantor Fitzgerald’s latest rating for AMGN stock - Knox Daily
Nutanix Inc [NTNX] Chief Financial Officer makes an insider sale of 24,316 shares worth 1,430,939. - Knox Daily
GSK’s Stock Market Adventure: 9.44% YTD Growth Amidst Volatility - The InvestChronicle
GSK Shares Experience Decline in Value - Knox Daily
Ratio Revelations: GSK Plc ADR (GSK)’s Financial Metrics in the Spotlight - The Dwinnex
Why GSK (GSK) is a Top Value Stock for the Long-Term - Yahoo Finance Australia
Things To Consider Before You Buy GSK Plc ADR (NYSE: GSK) - Stocks Register
GSK Plc ADR [GSK] Is Currently -0.31 below its 200 Period Moving Avg: What Does This Mean? - The DBT News
GSK Meets Study Goal for Co-Administered RSV-Shingles Vaccines - Zacks Investment Research
Behind GSK Plc ADR’s 52-Week Range: Uncovering Opportunities for Investors - The InvestChronicle
글락소스미스클라인 ADR (GSK) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.78%
0.74%
자본화:
|
볼륨(24시간):